Yubo International Biotech Reports Zero Revenue and Rising Losses in Challenging Q1 2025

Yubo International Biotech Limited (PINK: YBGJ) has recently released its quarterly financial performance for the period ending March 31, 2025. The review reflects a challenging environment for the company as it reported a lack of sales, continued operational losses, and an ongoing need for external financing.

Key Points from the Income Statement:

• Revenue: Sales for Q1 2025 were $0, a significant decline compared to $3,488 in Q1 2024.
• Cost of Goods Sold: Reported as $0, down from $827 in Q1 2024.
• Gross Profit: Went from $2,661 in Q1 2024 to $0 in Q1 2025.
• Total Operating Expenses: Increased to $467,299 from $412,082 year-over-year, primarily due to higher employee compensation and occupancy costs.
• Net Loss: Totaled $467,318 for Q1 2025, compared to a loss of $409,505 in Q1 2024.
• Net Loss per Share: Remained at $(0.00) per share, with 119,820,790 weighted average shares outstanding.
• Comprehensive Loss: Reported as $(388,410) for Q1 2025 compared to $(314,866) for Q1 2024.

Positive Aspects:

• The company's cash and cash equivalents increased to $9,773 from $7,015.
• There was a notable increase in 'Accumulated other comprehensive income' from $127,044 to $317,685, indicating potential favorable foreign currency translation adjustments.

Negative Aspects:

• Worrying operational losses raise serious concerns about the company's sustainability and ability to continue as a going concern.
• Negative working capital of $4,096,572 suggests liquidity challenges, reliance on shareholder loans for financing, and significantly high current liabilities amounting to $4,781,734.
• Potential regulatory and operational risks arising from the VIE structure and restrictions on foreign investments in China may jeopardize future operational capabilities.

Yubo International Biotech Limited's recent performance underscores a critical juncture for the company. With no sales revenue and ongoing net losses, the future growth and stability of the company hinge on finding new funding avenues and ensuring regulatory compliance, particularly in the PRC. Stakeholders should closely monitor these developments as the company navigates through a challenging landscape ahead.